GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

Campaigners in Northern Ireland have called for the introduction of a 'game-changing' drug that will prevent HIV. On Friday ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of the investigational, once-daily, oral, two-drug ...

A new way of getting high is “tearing the roof off” Fiji’s HIV infection rate, said The Fiji Times. “Bluetoothing” sees intravenous drug users “plunging a syringe” of methamphetamine into a vein, then ...